Abstract:OBJECTIVE:To prepare a transgenic tumor cell vaccine transfected the fusion gene of murine granulocyte-monocyte colony stimulating factor (mGM-CSF) and human interleukin-2 (hIL-2) using H22 cells, and explore its specific antitumor immunity against hepatocellular carcinoma.METHODS:The eukaryotic vector expressing the fusion gene mGM-CSF/hIL-2 was transfected into H22 cells followed by radiation exposure to construct the tumor cell vaccine, which was used to immunize Balb/c mice by subcutaneous inoculation. The mice inoculated subcutaneously with H22 cells, cells transfected with the empty vector pcDNA(+), or with PBS served as the controls. A week later, H22 cells were injected peritoneally into Balb/c mice for establishing the tumor-bearing model, and their serum levels of interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) were detected using enzyme-linked immunosorbent assay (ELISA) with the survival of the mice recorded. The spleen cells were obtained from the mice immunized with the tumor cell vaccine, the tumor-bearing mice and the normal control mice to assess their cytotoxicity against the parental H22 cells in vitro using (51)C(r)-release assay.RESULTS:The transgenic H22 cell vaccine transfected with mGM-CSF/hIL-2 fusion gene was successfully constructed. The killing rate of H22 cells by the spleen cells from the mice immunized with the transgenic cell vaccine was significantly higher than those by the spleen cells from the tumor-bearing mice or normal control mice (38.3% vs 13.6% and 7.5%, P<0.05). Serum IFN-gamma in the tumor-bearing mice immunized with the transgenic cell vaccine was significantly higher, and serum IL-10 significantly lower than those of the control groups (P<0.01). The survival time of the tumor-bearing mice injected with the transgenic cell vaccine was also significantly prolonged.CONCLUSION:Syngeneic tumor cell vaccine genetically modified by mGM-CSF/hIL-2 fusion gene transfection can elicit specific cellular immune response and enhance the host antitumor immune response to extend the survival time of tumor-bearing mice.

High cell-density fermentation of engineered E.coli and antitumor immunity of recombinant human MAGE3/HSP70 in vivo

Preparation of gene recombinant MAGE1/HSP70/MAGE3 by high cell density culture of E.coli.with DO fed-back control of nutrient feeding

Establishment of antigen MAGE-3 gene vaccine and primary study of its immune activity

Construction and Identification of Eukaryotic Expression Vector of MAGE-3-HSP70 Fusion Gene

Construction,expression and purification of a fusion gene of MAGE-n peptide with human heat shock protein 70

[Construction and Prokaryotic Expression of Recombinant Gene EGFRvIII HBcAg and Immunogenicity Analysis of the Fusion Protein].

Heat Shock Protein 70/MAGE-3 Fusion Protein Vaccine Can Enhance Cellular and Humoral Immune Responses to MAGE-3 in Vivo.

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Prokaryotic Expression, Purification of HSP65-MUC1 VNTR2 Fusion Protein and Primary Research on Its Tumoricidal Effect

Construction and immunologic competence of MAGE-1 gene vaccine

The Anti-Tumor Immune Response Induced by A Combination of Mage-3/Mage-N-Derived Peptides

Preparation of nanoemulsion-encapsulated tumor specific antigen and study on its character and antitumor immunity

[Preparation and Antitumor Immunity of Long Circulating Nano-Liposome Encapsulated Tumor Specific Antigen].

Heat Shock Protein 70 / MAGE-1 Tumor Vaccine Can Enhance the Potency of MAGE-1–specific Cellular Immune Responses in Vivo

Preparation and Antitumor Effects of Nanovaccines with MAGE-3 Peptides in Transplanted Gastric Cancer in Mice.

[Application of a Tumor Cell Vaccine Transfected with GM-CSF/IL-2 Fusion Gene for Specific Immunotherapy of Hepatocellular Carcinoma].

The Basic Study and Purification Strategy of MAGE-1/MAGE-3/Heat Shock Protein 70 Fusion Protein Tumor Vaccine

Prokaryotic Expression and Purification of MAGE-3 Gene and Preparation of Polyclonal Antibody Against MAGE-3

Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses

Anti-tumor Effect and Its Mechanism of Co-Administration of Fusion Proteins Hvegf121/βhcg and Mgm-Csf/βhcg

MAGE-3 peptide amphiphile micelle vaccine promote anti-tumor immunity in mice with stomach cancer